Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KVD900 for on-demand treatment of hereditary angioedema
NCT04208412Phase 2Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of sebetralstat in hereditary angioedema (HAE) (3 arms), sponsored by KalVista Pharmaceuticals. Primary endpoint: Time to Conventional Attack Treatment Use Within 12 Hours of Study Drug. Started Jul 2019; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04208412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208412.